# A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer

> **NCT04621370** · PHASE2 · UNKNOWN · sponsor: **Liz-Anne Lewsley** · enrollment: 48 (estimated)

## Conditions studied

- Rectal Cancer
- Rectal Adenocarcinoma
- Rectal Neoplasms

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** FOLFOX
- **RADIATION:** Short Course Radiotherapy (Arm A)
- **RADIATION:** Long course chemoradiation (Arm B)
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04621370
- **Lead sponsor:** Liz-Anne Lewsley
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-07
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2020-11-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04621370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04621370, "A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04621370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*